Faculty

TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of multiple myeloma.

LEARNING OBJECTIVES

• Understand how age, comorbidities, cytogenetic profile and fitness for stem cell transplantation influence the selection of first-line therapy for patients with newly diagnosed multiple myeloma (MM).
• Appreciate clinical trial data informing the front-line use of anti-CD38 monoclonal antibody therapy for patients with MM eligible for stem cell transplant, and identify those for whom a quadruplet regimen would be appropriate.
• Evaluate available research findings with anti-CD38 monoclonal antibody-containing regimens as front-line treatment for patients with MM deemed ineligible for stem cell transplant, and consider the current role of various evidence-based regimens in clinical practice.
• Customize the use of maintenance therapy in the transplant and nontransplant settings, considering recently published research and patient- and disease-related factors, including cytogenetic profile and depth of response to induction therapy.
• Implement a plan of care to recognize and manage side effects and toxicities associated with commonly used and emerging front-line regimens for MM.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/FirstLineTherapyMM25/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Xavier Leleu, MD, PhD
Professor, Head of Myeloma Clinic
Head of Department of Hematology
Hôpital La Miletrie
Poitiers University Hospital
Poitiers, France

Advisory Committees, Consulting Agreements and Data and Safety Monitoring Boards/Committees: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, GSK, Ichnos Glenmark Innovation, Janssen Biotech Inc, Kite, A Gilead Company, Novartis, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Takeda Pharmaceuticals USA Inc.

Peter Voorhees, MD
Professor of Medicine
Wake Forest University School of Medicine
Chief, Plasma Cell Disorders Division
Atrium Health/Levine Cancer Institute
Associate Director of Clinical Research
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Charlotte, North Carolina

Advisory Committees: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Johnson & Johnson, Kite, A Gilead Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Johnson & Johnson and Sanofi.

Release date: July 2025
Expiration date: July 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Ailawadhi S et al. Isatuximab subcutaneous by on-body injector versus isatuximab intravenous plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Phase III IRAKLIA study. J Clin Oncol 2025;[Online ahead of print]. Abstract

Badros A et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: The AURIGA study. Blood 2025;145(3):300-10. Abstract

Callander NS et al. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J 2024;14(1):69. Abstract

Dimopoulos MA et al. Daratumumab (DARA)/bortezomib/lenalidomide/dexamethasone (D‐VRd) with D‐R maintenance (maint) in transplant‐eligble (TE) newly diagnosed myeloma (NDMM): PERSEUS cytogenetic risk analysis. IMS 2024;Abstract OA-48.

Dimopoulos MA et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N Engl J Med 2024;392(18):1777-88. Abstract

Dimopoulos MA et al. Phase 3 randomized study of daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Primary results of the AQUILA study. ASH 2024;Abstract 773.

Facon T et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. New Engl J Med 2024;391:1597-609. Abstract

Facon T et al. Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa‐VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). IMS 2024;Abstract OA-49.

Foster L et al. Daratumumab plus lenalidomide (D-R) versus lenalidomide (R) alone as maintenance therapy in newly diagnosed multiple myeloma (NDMM) after transplant: Analysis of the phase 3 AURIGA study among clinically relevant subgroups. ASH 2024;Abstract 675.

Gay F et al. Analysis of sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III ISKIA trial). EHA 2025;Abstract S208.

Gay F et al. Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial). ASCO 2025;Abstract 7502.

Leleu X et al. Isatuximab subcutaneous via an on-body delivery system versus isatuximab intravenous, plus pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma: The randomized phase 3 IRAKLIA study. EHA 2025;Abstract S203.

Leleu X et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: The randomized phase 3 BENEFIT trial. Nat Med 2024;30:2235-41. Abstract

Mai EK et al. Impact of minimal residual disease on progression-free survival in patients with newly diagnosed multiple myeloma treated with isatuximab, lenalidomide, bortezomib and dexamethasone induction therapy in the phase 3 GMMG-HD7 trial. ASH 2024;Abstract 364.

Moreau P et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: Long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol 2024;25(8):1003-14. Abstract

Moreau P et al. Daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTD) followed by DARA maintenance in transplant-eligible (TE) newly diagnosed multiple MYELOMA (NDMM): >6-year update of CASSIOPEIA. EHA 2024;Abstract S204.

Perrot A et al. Minimal residual disease-driven strategy following isatuximab-carfilzomib-lenalidomide-dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma: Primary endpoints of the phase 3 MIDAS trial. EHA 2025;Abstract S205.

Perrot A et al. MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial. ASCO 2025;Abstract 7500.

Sonneveld P et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. New Engl J Med 2024;390:132-47. Abstract

Usmani SZ et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: The randomized phase 3 CEPHEUS trial. Nature Med 2025;31(4):1195-202. Abstract

Voorhees PM et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 2023;10:e825-37. Abstract

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia.

LEARNING OBJECTIVES

• Recall recent research findings affecting the clinical management of acute myeloid leukemia (AML) with FLT3 or IDH1/2 mutations and as applicable, adapt current treatment algorithms based upon these results.
• Evaluate available research evidence with the use of FLT3 inhibitors in combination with standard intensive induction and consolidation chemotherapy, and use this information to make appropriate treatment recommendations for patients with newly diagnosed AML harboring a FLT3 mutation.
• Develop strategies to optimally integrate approved FLT3 inhibitors into the care of patients with progressive AML harboring a FLT3 mutation.
• Analyze patient-specific factors and available clinical trial data to guide the selection of induction therapy for patients with newly diagnosed AML harboring an IDH1 or IDH2 mutation.
• Understand published data with and the current role of available IDH1/2 inhibitors for patients with relapsed/refractory AML and an IDH1 or IDH2 mutation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Video Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1 (video) and 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

Video Interview: ResearchToPractice.com/OncologyTodayAML24/Video and evaluation ResearchToPractice.com/OncologyTodayAML24/Video/CME.

Video Lecture: ResearchToPractice.com/OncologyTodayAML24/Presentation and evaluation ResearchToPractice.com/OncologyTodayAML24/Presentation/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Jorge Cortes, MD
Director, Georgia Cancer Center
Augusta University
Augusta, Georgia

Consulting Agreements: Ascentage Pharma, Bio-Path Holdings Inc, Novartis, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc, Terns Pharmaceuticals; Contracted Research: Ascentage Pharma, Bio-Path Holdings Inc, CytoAgents, Kura Oncology, Novartis, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Terns Pharmaceuticals; Stock Options/Stock — Public Companies: Bio-Path Holdings Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Daiichi Sankyo Inc and Rigel Pharmaceuticals Inc.

Release date: July 2025
Expiration date: July 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Cortes JE et al. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: A multicohort open-label phase 1/2 trial. J Hematol Oncol 2025;18(1):7. Abstract

DiNardo CD et al. Phase 1b/2 study of decitabine and venetoclax in combination with the targeted mutant IDH1 inhibitor olutasidenib for patients with relapsed/refractory AML, high risk MDS, or newly diagnosed AML not eligible for chemotherapy with an IDH1 mutation. ASH 2024;Abstract 1527.2.

Jiang B et al. Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib versus salvage chemotherapy in the phase 3 COMMODORE trial. EHA 2025;Abstract S143.

Levis M et al. The combination of a FLT3-ITD, NPM1mut and an epigenetic regulatory gene mutation confers unique sensitivity to quizartinib: Analysis from the QuANTUM-First trial. EHA 2025;Abstract S140.

Levis M et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol 2024;42(15):1766-75. Abstract

Levis MJ et al. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. Blood 2025;145(19):2138-48. Abstract

Levis MJ et al. Correlation of baseline gene mutations with quizartinib efficacy in patients with FLT3-ITD–positive newly diagnosed acute myeloid leukemia in the phase 3 QuANTUM-First trial. ASH 2024;Abstract 848.

Luger S et al. Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD negative rate: Results of the phase 2 randomized Precog 0905 study in newly diagnosed FLT3 mutated AML. ASH 2024;Abstract 221.

Marvin-Peek J et al. A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated hematologic malignancies: A 2024 update. ASH 2024;Abstract 219.

Montesinos P et al. Final results of Quiwi: A double blinded, randomized pethema trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD negative AML. ASH 2024;Abstract 1512.

Montesinos P et al. Trial in progress: The phase 3, randomized, double-blind, placebo-controlled QuANTUM-Wild study of quizartinib in combination with chemotherapy and as single-agent maintenance in newly diagnosed, FLT3-ITD–negative acute myeloid leukemia. ASH 2024;Abstract 1504.3.

Mosquera Orgueira A et al. Enhanced validation of the FLT3-like gene expression signature as a predictive biomarker for quizartinib response in FLT3-ITD negative acute myeloid leukemia: Expanded cohort and extended follow-up from the Pethema Quiwi trial. ASH 2024;Abstract 1552.

Short NJ et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol 2024;42(13):1499-508. Abstract

Short NJ et al. Long-term survival outcomes and cytogenetic/molecular patterns of relapse in adults with FLT3-mutated AML receiving frontline triplet therapy with a hypomethylating agent, venetoclax and FLT3 inhibitor. ASH 2024;Abstract 220.

Stone RM et al. 10 year follow-up of CALGB 10603/Ratify: Midostaurin versus placebo plus intensive chemotherapy in newly diagnosed FLT3 mutant acute myeloid leukemia patients aged 18-60 years. ASH 2024;Abstract 218.

Wang ES et al. Time to response and overall survival in patients with mIDH1 relapsed/refractory acute myeloid leukemia treated with olutasidenib. ASH 2024;Abstract 1514.

Wang J et al. Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. Leukemia 2024;38(11):2410-8. Abstract

Yilmaz M et al. Phase I/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML. EHA 2025;Abstract S142.

Faculty

TARGET AUDIENCE
This program is intended for medical and gynecologic oncologists, gynecologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gynecologic cancers.

LEARNING OBJECTIVES

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and appropriately counsel patients regarding personalized treatment recommendations.
• Evaluate the biological rationale for and published data with PARP inhibitors in combination with other systemic therapies, and consider the current and potential clinical and research implications of these findings for OC management.
• Appraise relevant biological, patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and optimally incorporate this novel strategy into the care of patients with microsatellite instability-high/mismatch repair (MMR)-deficient and microsatellite-stable/MMR-proficient disease.
• Understand the available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
• Interrogate published efficacy and safety findings with anti-PD-1/PD-L1 antibodies in combination with other local or systemic therapies for cervical cancer, and effectively integrate immune checkpoint inhibition into patient care.
• Evaluate published clinical research documenting the efficacy of HER2-targeted agents and regimens for patients with HER2-overexpressing gynecologic cancers, and consider the role of various approaches in disease management.
• Describe the scientific justification for, published data with and ongoing research with novel agents and strategies for gynecologic cancers, and effectively prioritize clinical trial opportunities for eligible patients.
• Evaluate the potential benefits of measuring circulating tumor DNA to assess for the absence or presence of molecular residual disease during and after treatment for various gynecologic cancers, and consider the current and future utility of this strategy in clinical practice.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YiR2024/Gyn/Presentations/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Susana Banerjee, MBBS, MA, PhD
Consultant Medical Oncologist
The Royal Marsden NHS Foundation Trust
Professor in Women’s Cancers
The Institute of Cancer Research, London
President
Royal Society of Medicine, Oncology Section
London, United Kingdom

Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, BioNTech SE, Eisai Inc, Epsilogen, Genmab US Inc, Gilead Sciences Inc, GSK, Greywolf Therapeutics, ImmunoGen Inc, Incyte Corporation, ITM Oncologics GmbH, Lilly, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, OncXerna Therapeutics Inc, pharmaand GmbH, Seagen Inc, TORL BioTherapeutics, Verastem Inc, Zymeworks Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, GSK, ImmunoGen Inc, Verastem Inc; Nonrelevant Financial Relationships: Perci Health.

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Day One Biopharmaceuticals, GSK, NextCure, Novartis, Tango Therapeutics; Consulting Agreements: Whitehawk Therapeutics; Data and Safety Monitoring Boards/Committees: Daiichi Sankyo Inc, MacroGenics Inc, Mural Oncology Inc, Symphogen A/S.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, and Natera Inc

Release date: July 2025
Expiration date: July 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Banerjee S et al. Avutometinib + defactinib in recurrent low-grade serous ovarian cancer (ENGOT-ov60/GOG-3052/RAMP 201): Dose intensity and subgroup analysis. SGO 2024;Abstract 814605.

Duska LR et al. Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. ASCO 2025;Abstract LBA5504.

Eskander RN et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med 2025;31(5):1539-46. Abstract

Graybill WS et al. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study. Int J Gynecol Cancer 2024;34(7):1041-50. Abstract

Hardy-Bessard A-C et al. FIRST/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC). ASCO 2025;Abstract LBA5506.

Lorusso D et al. Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: Final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. Ann Oncol 2025;36(1):65-75. Abstract

Lorusso D et al. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Int J Gynecol Cancer 2024;34(4):550-8. Abstract

Makker V et al. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol 2024;185:202-11. Abstract

Mayadev J et al. Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses. ASCO 2025;Abstract 5502.

Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract

Mirza MR et al. Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial. ESMO Gynaecological Cancers Congress 2024;Abstract 38MO.

Monk BJ et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol 2024;35(11):981-92. Abstract

Moore KN et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: biomarkers, histological heterogeneity, baseline circulating tumor DNA, and efficacy in the DUO-E mismatch repair proficient subpopulation. SGO 2025;Abstract 922975.

Moore K et al. Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study. SGO 2024;Abstract.

Oaknin A et al. Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: Post hoc analysis of DESTINY-PanTumor02. Adv Ther 2024;41(11):4125-39. Abstract

Olawaiye AB et al. Relacorilant and nab-paclitaxel in patients with platinum resistant ovarian cancer (ROSELLA): An open-label, randomised, controlled, phase 3 trial. Lancet 2025;405(10496):2205-16. Abstract

Powell MA et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol 2024;35(8):728-38. Abstract

Recio F et al. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies. Gynecol Oncol 2024;182:63-9. Abstract

Slomovitz BM et al. Pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy for newly diagnosed, high-risk endometrial cancer: Results in mismatch repair-deficient tumors. J Clin Oncol 2025;43(3):251-9. Abstract

Trillsch F et al. Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O. ESMO Gynaecological Cancers Congress 2024;Abstract 43O.

Van Gorp T et al. Final overall survival analysis among patients with FRα-positive, platinum-resistant ovarian cancer (PROC) treated with mirvetuximab soravtansine (MIRV) vs investigator’s choice chemotherapy (ICC) in the phase 3 MIRASOL (GOG 3045/ENGOT-ov55) study. SGO 2025;Abstract 939696.

Vergote I et al. Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA non-mutated epithelial ovarian cancer: Results from the randomized phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 study. ESGO 2025;Abstract 128.

Vergote I et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med 2024;391(1):44-55. Abstract

Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA. ASCO 2025;Abstract 5512.

Faculty

TARGET AUDIENCE
This program is intended for medical and gynecologic oncologists, gynecologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gynecologic cancers.

LEARNING OBJECTIVES

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and appropriately counsel patients regarding personalized treatment recommendations.
• Evaluate the biological rationale for and published data with PARP inhibitors in combination with other systemic therapies, and consider the current and potential clinical and research implications of these findings for OC management.
• Appraise relevant biological, patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and optimally incorporate this novel strategy into the care of patients with microsatellite instability-high/mismatch repair (MMR)-deficient and microsatellite-stable/MMR-proficient disease.
• Understand the available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
• Interrogate published efficacy and safety findings with anti-PD-1/PD-L1 antibodies in combination with other local or systemic therapies for cervical cancer, and effectively integrate immune checkpoint inhibition into patient care.
• Evaluate published clinical research documenting the efficacy of HER2-targeted agents and regimens for patients with HER2-overexpressing gynecologic cancers, and consider the role of various approaches in disease management.
• Describe the scientific justification for, published data with and ongoing research with novel agents and strategies for gynecologic cancers, and effectively prioritize clinical trial opportunities for eligible patients.
• Evaluate the potential benefits of measuring circulating tumor DNA to assess for the absence or presence of molecular residual disease during and after treatment for various gynecologic cancers, and consider the current and future utility of this strategy in clinical practice.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YiR2024/Gyn/Presentations/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Susana Banerjee, MBBS, MA, PhD
Consultant Medical Oncologist
The Royal Marsden NHS Foundation Trust
Professor in Women’s Cancers
The Institute of Cancer Research, London
President
Royal Society of Medicine, Oncology Section
London, United Kingdom

Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, BioNTech SE, Eisai Inc, Epsilogen, Genmab US Inc, Gilead Sciences Inc, GSK, Greywolf Therapeutics, ImmunoGen Inc, Incyte Corporation, ITM Oncologics GmbH, Lilly, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, OncXerna Therapeutics Inc, pharmaand GmbH, Seagen Inc, TORL BioTherapeutics, Verastem Inc, Zymeworks Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, GSK, ImmunoGen Inc, Verastem Inc; Nonrelevant Financial Relationships: Perci Health.

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Day One Biopharmaceuticals, GSK, NextCure, Novartis, Tango Therapeutics; Consulting Agreements: Whitehawk Therapeutics; Data and Safety Monitoring Boards/Committees: Daiichi Sankyo Inc, MacroGenics Inc, Mural Oncology Inc, Symphogen A/S.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GSK, and Natera Inc

Release date: July 2025
Expiration date: July 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Banerjee S et al. Avutometinib + defactinib in recurrent low-grade serous ovarian cancer (ENGOT-ov60/GOG-3052/RAMP 201): Dose intensity and subgroup analysis. SGO 2024;Abstract 814605.

Duska LR et al. Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. ASCO 2025;Abstract LBA5504.

Eskander RN et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med 2025;31(5):1539-46. Abstract

Graybill WS et al. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study. Int J Gynecol Cancer 2024;34(7):1041-50. Abstract

Hardy-Bessard A-C et al. FIRST/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC). ASCO 2025;Abstract LBA5506.

Lorusso D et al. Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: Final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. Ann Oncol 2025;36(1):65-75. Abstract

Lorusso D et al. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Int J Gynecol Cancer 2024;34(4):550-8. Abstract

Makker V et al. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol 2024;185:202-11. Abstract

Mayadev J et al. Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses. ASCO 2025;Abstract 5502.

Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract

Mirza MR et al. Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial. ESMO Gynaecological Cancers Congress 2024;Abstract 38MO.

Monk BJ et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol 2024;35(11):981-92. Abstract

Moore KN et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: biomarkers, histological heterogeneity, baseline circulating tumor DNA, and efficacy in the DUO-E mismatch repair proficient subpopulation. SGO 2025;Abstract 922975.

Moore K et al. Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study. SGO 2024;Abstract.

Oaknin A et al. Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: Post hoc analysis of DESTINY-PanTumor02. Adv Ther 2024;41(11):4125-39. Abstract

Olawaiye AB et al. Relacorilant and nab-paclitaxel in patients with platinum resistant ovarian cancer (ROSELLA): An open-label, randomised, controlled, phase 3 trial. Lancet 2025;405(10496):2205-16. Abstract

Powell MA et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol 2024;35(8):728-38. Abstract

Recio F et al. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies. Gynecol Oncol 2024;182:63-9. Abstract

Slomovitz BM et al. Pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy for newly diagnosed, high-risk endometrial cancer: Results in mismatch repair-deficient tumors. J Clin Oncol 2025;43(3):251-9. Abstract

Trillsch F et al. Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O. ESMO Gynaecological Cancers Congress 2024;Abstract 43O.

Van Gorp T et al. Final overall survival analysis among patients with FRα-positive, platinum-resistant ovarian cancer (PROC) treated with mirvetuximab soravtansine (MIRV) vs investigator’s choice chemotherapy (ICC) in the phase 3 MIRASOL (GOG 3045/ENGOT-ov55) study. SGO 2025;Abstract 939696.

Vergote I et al. Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA non-mutated epithelial ovarian cancer: Results from the randomized phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 study. ESGO 2025;Abstract 128.

Vergote I et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med 2024;391(1):44-55. Abstract

Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA. ASCO 2025;Abstract 5512.

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia.

LEARNING OBJECTIVES

• Appreciate the incidence of KMT2A translocations or NPM1 mutations in patients with acute leukemias, and understand the significance of these abnormalities for prognosis, biomarker assessment and current management.
• Describe the mechanism of action of menin inhibitors and review the rationale for their activity in patients with KMT2A-rearranged and NPM1-mutant acute leukemias.
• Evaluate available efficacy and safety data with the use of menin inhibitors in patients with previously treated KMT2A-rearranged acute leukemias, and optimally integrate the single FDA-approved agent into current management algorithms.
• Assess published and emerging clinical trial findings with available and investigational menin inhibitors for the treatment of NPM1-mutant acute myeloid leukemia (AML), and consider the implications for current and future management.
• Understand the spectrum, incidence and severity of side effects, including differentiation syndrome and cardiac toxicity, associated with menin inhibitors, and develop appropriate monitoring and management protocols.
• Appreciate the rationale for combining menin inhibitors with other standard regimens in AML and recall ongoing trials evaluating these novel strategies.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Video Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) and 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

Video Interview: ResearchToPractice.com/OncologyTodayMeninAML24/Video and evaluation ResearchToPractice.com/OncologyTodayMeninAML24/Video/CME.

Video Lecture: ResearchToPractice.com/OncologyTodayMeninAML24/Presentation and evaluation ResearchToPractice.com/OncologyTodayMeninAML24/Presentation/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ghayas Issa, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consultancy or Advisory Boards: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Biostate, Crossbow Therapeutics, Kura Oncology, Novartis, Sanofi, Syndax Pharmaceuticals; Research Funding: Astex Pharmaceuticals, Celgene Corporation, Crossbow Therapeutics, Cullinan Therapeutics, Daiichi Sankyo Inc, Kura Oncology, Merck, Novartis, Pupil Bio, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals; Scientific Advisory Boards: Biostate, Pupil Bio.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Johnson & Johnson, Kura Oncology, and Syndax Pharmaceuticals.

Release date: July 2025
Expiration date: July 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Arellano ML et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: The AUGMENT-101 study. Blood 2025;[Online ahead of print]. Abstract

Issa GC et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol 2025;43(1):75-84. Abstract

Issa GC et al. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 2023;7(6):933-42. Abstract

Issa GC et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 2023;615(7954):920-4. Abstract

Mahdavi L et al. Clonal evolution mediates menin-inhibitor resistance in KMT2A-rearranged leukemias. bioRxiv 2023. Abstract

Perner F et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature 2023;615:913-9. Abstract

Soto-Feliciano YM et al. A molecular switch between mammalian MLL complexes dictates response to menin-MLL inhibition. Cancer Discov 2023;13(1):146-69. Abstract

Wang ES et al. Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study. ASCO 2025;Abstract 6506

Wang ES et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol 2024;25:1310-24. Abstract

Faculty

TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.

LEARNING OBJECTIVES

• Individualize the selection of systemic therapy for newly diagnosed chronic lymphocytic leukemia (CLL), considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences for time-limited or continuous treatment.
• Appreciate the scientific rationale for the investigation of combined Bruton tyrosine kinase (BTK) and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with CLL.
• Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory (R/R) CLL.
• Discuss available clinical research findings demonstrating the efficacy and safety of noncovalent BTK inhibitors in CLL, and use this information to effectively incorporate these agents into the care of patients with R/R disease.
• Evaluate the biological rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy for CLL, and identify patients for whom this novel therapeutic strategy would be appropriate.
• Implement a plan of care to recognize and manage side effects and toxicities associated with available systemic therapies commonly employed in the treatment of CLL.
• Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL, and as applicable, refer eligible patients for clinical trial participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2025/CLL/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Catherine C Coombs, MD
Associate Clinical Professor
Division of Hematology/Oncology
Department of Medicine
UCI Health
Orange County, California

Advisory Committees: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MingSight Pharmaceuticals, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Lilly, Octapharma; Contracted Research: AbbVie Inc, BeiGene Ltd, Carna Biosciences, Lilly; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Lilly; Stock Options/Stock — Public Companies: Geron Corporation, Pfizer Inc.

William G Wierda, MD, PhD
Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr Elihu Estey
Section Chief, Chronic Lymphocytic Leukemia
Center Medical Director
Department of Leukemia, Division of Cancer Medicine
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: BeiGene Ltd, Numab Therapeutics AG; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bristol Myers Squibb, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Nurix Therapeutics Inc, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company; Nonrelevant Financial Relationships: National Comprehensive Cancer Network (Chair, CLL), Support by the NIH/NCI under award number P30 CA016672 and use of MD Anderson Cancer Center Support Grant (CCSG) shared resources.

SURVEY PARTICIPANTS
John N Allan, MD — Advisory Committees: NeoGenomics; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company; Contracted Research: BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Merck; Speakers Bureaus: AbbVie Inc, BeiGene Ltd. Matthew S Davids, MD, MMSc — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Galapagos NV, Genentech, a member of the Roche Group, Genmab US Inc, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Nuvalent, Schrödinger, Secura Bio, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Ascentage Pharma, MEI Pharma Inc, Novartis; Nonrelevant Financial Relationships: UpToDate. Jeff Sharman, MD — Consulting Agreements and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly, Merck. Tanya Siddiqi, MD — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Celgene Corporation, Gilead Sciences Inc; Contracted Research: Bristol Myers Squibb; Data and Safety Monitoring Boards/Committees: BeiGene Ltd; Speakers Bureaus: AstraZeneca Pharmaceuticals LP.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from Lilly.

Release date: July 2025
Expiration date: July 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Wierda

Module 1: Selection and Sequencing of Therapy for Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)

Escalón MP et al. BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress). iwCLL 2023;Abstract 1548596.

Eyre TA et al. BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASCO 2023;Abstract TPS7583.

Jurczak W et al. BRUIN CLL-313: A phase 3 open-label, randomized study of pirtobrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress). ASH 2021;Abstract 3732.

Mato AR et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed / refractory CLL/SLL: Additional patients and extended follow-up from the phase 1/2 BRUIN study. ASH 2022;Abstract 961.

Ng J et al. Cardiovascular adverse effects of novel Bruton tyrosine kinase inhibitors: What all cardiologists should know. American College of Cardiology, August 16, 2023. https://www.acc.org/Latest-in-Cardiology/Articles/2023/08/15/16/45/CV-Adverse-Effects-of-Novel-Bruton-Tyrosine-Kinase-Inhibitors

Sharman JP et al. BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH 2024;Abstract 886.

Wierda WG et al. Lisocabtagene maraleucel (liso-cel) combined with ibrutinib (ibr) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary results from the open-label, phase 1/2 Transcend CLL 004 study. ASH 2024;Abstract 887.

Module 3: Novel Agents and Strategies for RR CLL

Danilov A et al. Epcoritamab monotherapy in patients (Pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): Results from CLL expansion and optimization cohorts of Epcore CLL-1. ASH 2024;Abstract 883.

Shah NN et al. Efficacy and safety of the Bruton’s tyrosine kinase (BTK) degrader NX-5948 in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Updated results from an ongoing phase 1a/b study. ASH 2024;Abstract 884.

Thompson MC et al. Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 cadance-101 study. ASH 2024​;Abstract 885.

 

Dr Coombs

Module 2: First-Line Therapy for CLL

Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. EHA 2023;Abstract S145.

Barr PM et al. Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv 2022;6(11):3440-50. Abstract

Brown JR et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med 2025;392(8):748-62. Abstract

Brown JR et al. Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter, open-label, randomized, phase 3 AMPLIFY trial. ASH 2024;Abstract 1009.

Brown JR et al. Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL). ASH 2023;Abstract 202.

Burger J et al. Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2024;Abstract P670.

Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol 2021;39(31):3441-52. Abstract

Davids MS et al. Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naïve chronic lymphocytic leukemia population enriched for high-risk disease. J Clin Oncol 2025;43(7):788-99. Abstract

Eichhorst B et al. Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA/CLL13 trial. EHA 2022;Abstract LB2365.

Fürstenau M et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2024;25(6):744-59. Abstract

O’Brien SM et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol 2021;11. Abstract

Ryan CE et al. MAJIC: A phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol 2022;18(33):3689-99. Abstract

Shadman M et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: Median 5-year follow-up of SEQUOIA. J Clin Oncol 2025;43(7):780-7. Abstract

Sharman JP et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of Elevate-TN. ASH 2023;Abstract 636.

Sharman JP et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. Lancet 2020;395(10232):1278-91. Abstract

Soumerai JD et al. Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: Data from an ongoing phase 1/1b study BGB-11417-101. ASH 2024;Abstract 1012.

Faculty

TARGET AUDIENCE
This program is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of renal cell carcinoma.

LEARNING OBJECTIVES

• Appraise available clinical trial data evaluating anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for previously untreated metastatic renal cell carcinoma (mRCC), and counsel patients about the risks and benefits of these novel regimens.
• Review the biological rationale for the investigation of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for patients with mRCC, and appreciate long-term research documenting the effectiveness of this approach.
• Develop a rational approach to the sequencing of systemic therapies for patients with advanced RCC who experience disease progression on first-line treatment, incorporating multikinase inhibitors, HIF-2α inhibitors, immunotherapeutic agents and other options.
• Appreciate published clinical research evaluating available and investigational agents for non-clear cell RCC, and consider the applicability of these strategies in patient care.
• Recall available and emerging data with other novel and investigational agents and strategies currently in testing for RCC, and as applicable, refer eligible patients for clinical trial participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2025/RCC/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Professor Laurence Albiges, MD, PhD
Medical Oncologist
Chair, Medical Oncology Department
Gustave Roussy Cancer Center
Villejuif, France

Advisory/Consulting/Honoraria (All Paid to Institution): Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Merck, MSD, Novartis, Pfizer Inc, Roche Laboratories Inc, Telix Pharmaceuticals Limited, Xencor.

Tian Zhang, MD, MHS
Associate Professor
Director of Clinical Research
Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Associate Director for Clinical Research
Simmons Comprehensive Cancer Center
Dallas, Texas

Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Gilead Sciences Inc, Janssen Biotech Inc, Lilly, Merck, Novartis, Pfizer Inc, Sanofi; Consulting Agreements: Aptitude Health, DAVA Oncology, Pfizer Inc, Vaniam Group; Contracted Research: ALX Oncology, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, Janux Therapeutics, Lilly, Merck, OncoC4, Pfizer Inc, Tempus; Nonrelevant Financial Relationships: Mashup Media LLC, MJH Life Sciences, PeerView.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Aveo Pharmaceuticals and Exelixis Inc.

Release date: July 2025
Expiration date: July 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Zhang

Module 1: Metastatic Clear Cell RCC

Albiges L et al. Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. Genitourinary Cancers Symposium 2025;Abstract 438.

Braun DA et al. Beyond conventional immune-checkpoint inhibition – Novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol 2021;18(4):199-214. Abstract

Motzer RJ et al. Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial. Genitourinary Cancers Symposium 2025;Abstract 439.

Motzer RJ et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol 2024;42(11):1222-8. Abstract

Motzer R et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289-300. Abstract

Rini BI et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. ASCO 2023;Abstract LBA4501.

Zhang T et al. Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated on the phase 3 PDIGREE (Alliance A031704) trial: Results from step 1 analysis. ASCO 2025;Abstract 4516.

Zhu S et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 2021;14(1):156. Abstract

 

Prof Albiges

Module 3: Non-Clear Cell RCC

Albiges L et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): A single-arm, multicentre, phase 2 trial. Lancet Oncol 2023;24(8):881-91. Abstract

Albiges L et al. Non-clear cell renal cell carcinomas: From shadow to light. J Clin Oncol 2018;36(36):3624-31. Abstract

Bergmann L et al. Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial. ESMO 2024;Abstract LBA75.

Choueiri TK et al. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: The SAVOIR phase 3 randomized clinical trial. JAMA Oncol 2020;6(8):1247-55. Abstract

Fitzgerald KN et al. Cabozantinib plus nivolumab in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial. Eur Urol 2024;86(2):90-4. Abstract

Lee J-L et al. Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B. ESMO 2021;Abstract 662P.

McDermott DF et al. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol 2021;39(9):1029-39. Abstract

Négrier S et al. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. Eur J Cancer 2020;129:107-16. Abstract

Pal SK et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: A randomised, open-label, phase 2 trial. Lancet 2021;397(10275):695-703. Abstract

Salgia NJ et al. Renal cell carcinoma of variant histology: New biologic understanding leads to therapeutic advances. Am Soc Clin Oncol Educ Book 2024;44(3). Abstract

Srinivasan R et al. Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. ASCO 2020;Abstract 5004.

Suárez C et al. Phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). J Clin Oncol 2023;41(14):2493-502. Abstract

Tykodi SS et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer 2022;10(2). Abstract

Vogelzang NJ et al. Safety and efficacy of nivolumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase IIIb/IV CheckMate 374 study. Clin Genitourin Cancer 2020;18(6):461-8.e3. Abstract

Voss MH et al. First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study. Genitourinary Cancers Symposium 2024;Abstract 2.

 

Module 5: ASCO 2025

Chahoud J et al. Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study. ASCO 2025;Abstract 4515.

Faculty

TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of soft tissue sarcoma and related connective tissue disorders.

LEARNING OBJECTIVES

• Recognize the histologic diversity of soft tissue sarcomas (STS), and appreciate the importance of appropriate assessment and accurate diagnosis to facilitate optimal treatment and long-term outcomes for patients.
• Consider the influence of patient age, histology, extent of disease and other clinical and biological factors on the selection and sequencing of therapy for STS.
• Explore the clinical trial database supporting the use of agents such as multitargeted tyrosine kinase inhibitors, mTOR inhibitors, EZH2 inhibitors and T-cell receptor therapies that have demonstrated activity in various subtypes of STS, and use this information to identify patients for whom treatment with these strategies may be appropriate.
• Understand the incidence, risk factors, etiology and clinical presentation of desmoid tumors in order to optimally diagnose patients with this disease.
• Evaluate the scientific rationale for targeting the gamma secretase complex and Notch pathway as a therapeutic approach for desmoid tumors, and review available research establishing the efficacy and clinical role of this novel strategy.
• Assess the biological rationale for the evaluation of colony-stimulating factor-1 receptor inhibitors in the treatment of tenosynovial giant cell tumors, and consider the current role of these agents in patient care.
• Recall new data with investigational agents and strategies demonstrating promising activity for STS and other connective tissue neoplasms, and appropriately refer eligible patients for trial participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2025/STS/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Rashmi Chugh, MD
Professor of Internal Medicine
Division of Hematology/Oncology
Rogel Comprehensive Cancer Center
University of Michigan
Ann Arbor, Michigan

Advisory Committees: Deciphera Pharmaceuticals Inc, Inhibrx, Recordati Rare Diseases; Contracted Research: Adaptimmune, Astex Pharmaceuticals, Ayala Pharmaceuticals, Cogent Biosciences, Inhibrx, Kronos Bio, Pfizer Inc, PharmaMar, Polaris Pharmaceuticals.

Mrinal Gounder, MD
Associate Attending
Sarcoma Medical Oncology, Early Drug Development (Phase I)
Physician Ambassador – India and Asia, Bobst International Center
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell School of Medicine, Cornell University
New York, New York

Consulting Agreements: Aadi Bioscience, Avacta Therapeutics, Ayala Pharmaceuticals, Epizyme Inc, Ikena Oncology, Kura Oncology, Orion Corporation, Parabilis Medicines, Rain Oncology, Regeneron Pharmaceuticals Inc, Syros Pharmaceuticals Inc; Contracted Research: Avacta Therapeutics, Ayala Pharmaceuticals, Ikena Oncology, Immunome, Ipsen Biopharmaceuticals Inc, Kura Oncology, Orion Corporation, Parabilis Medicines, Pyxis Oncology, Tango Therapeutics, Vivace Therapeutics; Data and Safety Monitoring Boards/Committees: Kura Oncology.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Aadi Bioscience and SpringWorks Therapeutics Inc.

Release date: July 2025
Expiration date: July 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Chugh

Chen AP et al. Atezolizumab for advanced alveolar soft part sarcoma. N Engl J Med 2023;389(10):911-21. Abstract

D’Angelo SP et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): An international, open-label, phase 2 trial. Lancet 2024;403(10435):1460-71. Abstract

D’Angelo SP et al. Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis. ASCO 2021;Abstract 11521.

Gounder MM et al. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Cancer 2021;127(8):1311-7. Abstract

Gounder M et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: An international, open-label, phase 2 basket study. Lancet Oncol 2020;21(11):1423-32. Abstract

Judson I et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol 2014;15(4):415-23. Abstract

Seddon B et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): A randomised controlled phase 3 trial. Lancet Oncol 2017;18(10):1397-110. Abstract

Wagner AJ et al. Phase II trial of nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (AMPECT): Long-term efficacy and safety update. J Clin Oncol 2024;42(13):1472-6. Abstract

 

Dr Gounder

Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer 2020;127:96-107. Abstract

Gelderblom H et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024;403(10445):2709-19. Abstract

Gounder M et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med 2023;388(10):898-912. Abstract

Kasper B et al. DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT). ESMO 2022;Abstract LBA2.

Niu X et al. MANEUVER: A phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients. Future Oncol 2024:1-8. Abstract

Penel N. TIKIN away: Expanding the role of tyrosine kinase inhibitors for the treatment of sarcomas. ASCO 2025;Oral Abstract Session.

Tap WD et al. The MOTION study: A randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor. Future Oncol 2024;20(10):593-601. Abstract

Tap WD et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): A randomised phase 3 trial. Lancet 2019;394(10197):478-87. Abstract

Faculty

TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

LEARNING OBJECTIVES

• Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory multiple myeloma (MM).
• Evaluate the biological rationale for and published research information with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM, and identify patients for whom this novel approach should be considered and/or recommended.
• Assess available findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and recognize patients for whom treatment with one of these novel agents would be appropriate.
• Review recently presented clinical research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy, and recognize the potential clinical role of this form of treatment.
• Recall the mechanisms of action of and available research data with other novel investigational agents and strategies for MM, and counsel appropriate patients about participation in relevant clinical trials.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2025/MM/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ajay K Nooka, MD, MPH
Professor, Department of Hematology and Medical Oncology
Director, Myeloma Program
Associate Director of Clinical Research
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Advisory Boards and Consulting Agreements (Honoraria): Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Cellectar Biosciences Inc, GSK, Janssen Biotech Inc, K36 Therapeutics, Kite, A Gilead Company, ONK Therapeutics, Opna Bio, Pfizer Inc, Sanofi, Sebia; Data and Safety Monitoring Boards/Committees: Janssen Biotech Inc; Grant/Research Support (for Investigator-Initiated Studies): Amgen Inc, GSK, Janssen Biotech Inc, Merck, Takeda Pharmaceuticals USA Inc; Grant/Research Support (to University): Amgen Inc, Arch Oncology, Bristol Myers Squibb, Cellectis, Chinook Therapeutics, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Merck, Opna Bio, Pfizer Inc, Takeda Pharmaceuticals USA Inc.

Paul G Richardson, MD
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Oncopeptides.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

These activities are supported by an educational grant from GSK.

Release date: July 2025
Expiration date: July 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Dr Richardson

Beksac M et al. Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf). ASCO 2025;Abstract 7544.

Costa LJ et al. Mezigdomide (MEZI) in novel-novel combinations for relapsed or refractory multiple myeloma (RRMM): Preliminary results from the CA057-003 trial. ASH 2024;Abstract 677.

Dimopoulos MA et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 2024;391(5):408-21. Abstract

Dimopoulos MA et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): A phase 3, open-label, randomised study. Lancet Haematol 2023;10(10):e801-12. Abstract

Hartley-Brown MA et al. Mezigdomide—a novel cereblon E3 ligase modulator under investigation in relapsed/refractory multiple myeloma. Cancers (Basel) 2024;16(6):1166. Abstract

Hattin R et al. Incidence of ocular toxicities in patients with relapsed/refractory multiple myeloma treated with belantamab mafodotin: A systematic review and meta-analysis of phase 3 randomized controlled trials. ASCO 2024;Abstract 12040.

Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2024;391(5):393-407. Abstract

Hungria V et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial. ASH 2024;Abstract 772.

Hungria VTM et al. Impact of long-term treatment with belantamab mafodotin on safety and efficacy outcomes in patients with relapsed/refractory multiple myeloma in DREAMM-3. ASH 2023;Abstract 3357.

Korst CLBM et al. Iberdomide combined with low-dose cyclophosphamide and dexamethasone in relapsed/refractory multiple myeloma (IBERCD): First results of the phase 2 ICON study. EHA 2024;Abstract P899.

Lasica M et al. A phase I/II single arm study of belantamab mafodotin, carfilzomib and dexamethasone in patients with relapsed multiple myeloma: Planned interim analysis of safety and efficacy. Amarc 19-02 Belacard study. ASH 2023;Abstract 2012.

Liu Y et al. Targeting Ikaros and Aiolos: Reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. Expert Rev Hematol 2024;17(8):445-65. Abstract

Lonial S et al. Iberdomide (IBER) in combination with dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM): Results from the anti-B-cell maturation antigen (BCMA)-exposed cohort of the CC-220-MM-001 trial. ASH 2022;Abstract 1918.

Lonial S et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): A multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol 2022;9(11):e822-32. Abstract

Lonial S et al. Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (PTS) with relapsed/refractory multiple myeloma (RRMM). EHA 2021;Abstract S187.

Lonial S et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 2021;127(22):4198-212. Abstract

Lonial S et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21(2):207-21. Abstract

Nooka AK et al. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer 2023;129(23):3746-60. Abstract

Nooka AK et al. DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM). ASCO 2020;Abstract 8502.

Oriol A et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial. IMS 2023;Abstract OA-49.

Popat R et al. Results from arm A of phase 1/2 DREAMM-6 trial: Belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J 2024;14(1):184. Abstract

Popat R et al. DREAMM-6: Safety, tolerability and clinical activity of belantamab mafodotin (Belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple myeloma (RRMM). ASH 2020;Abstract 1419.

Richardson PG et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the CC-92480-MM-002 trial. ASH 2023;Abstract 1013.

Richardson PG et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 2023;389(11):1009-22. Abstract

Richardson PG et al. Mezigdomide (CC-92480), a potent, novel cereblon E3 ligase modulator (CELMoD), combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Preliminary results from the dose-expansion phase of the CC-92480-MM-001 trial. ASH 2022;Abstract 568.

Richardson PG et al. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: Analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J 2020;10(10):106. Abstract

Sandhu I et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated results from the CC-92480-MM-002 trial. ASH 2024;Abstract 1025.

Touzeau C et al. All-oral triplet iberdomide ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D. EHA 2024;Abstract P916.

White D et al. Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial. ASCO 2025;Abstract 7532.

 

Dr Nooka

Garfall AL et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. ASCO 2024;Abstract 7540.

Hansen DK et al. Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma. J Clin Oncol 2025;43(13):1597-609. Abstract

Khan E et al. Comparative efficacy of idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma: Real-world analysis of overall survival and time to next treatment. ASH 2025;Abstract e19532.

Nooka AK et al. Efficacy and safety of less frequent dosing with elranatamab (ELRA) in patients with relapsed or refractory multiple myeloma (RRMM): A US subgroup analysis from MagnetisMM-3. ASCO 2025;Abstract 7549.

Rasche L et al. Efficacy and safety from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: Analyses at an extended median follow-up. ASCO 2025;Abstract 7528.

Sidana S et al. Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses. ASCO 2025;Abstract 7539.

Tomasson M et al. Long-term efficacy and safety of elranatamab monotherapy in the phase 2 Magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM). ASH 2023;Abstract 3385.

Usmani SZ et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. ASCO 2023;Abstract 8034.

Faculty

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

LEARNING OBJECTIVES

• Define endocrine resistance in patients with HR-positive metastatic breast cancer (mBC), and integrate available nonhormonal therapies into the care of these individuals.
• Consider relevant biological, patient, psychosocial and treatment-related factors to personalize the selection and sequencing of therapy for individuals diagnosed with endocrine therapy resistant HR-positive mBC.
• Appraise available clinical research results establishing the safety and efficacy of HER2-directed antibody-drug conjugates (ADCs) for patients with HR-positive, HER2-low and HER2-ultralow mBC, and formulate a plan to optimally incorporate this therapeutic strategy into the treatment algorithm for appropriately selected patients.
• Interrogate published Phase III research findings documenting the efficacy of TROP2-directed ADCs for patients with HR-positive mBC to determine the current clinical applicability of these approaches.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Interview: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Video Lecture: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 0.75 (video) and 1 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

Video Interview: ResearchToPractice.com/OncologyToday25/mBC/1/Video and evaluation ResearchToPractice.com/OncologyToday25/mBC/1/Video/CME.

Video Lecture: ResearchToPractice.com/OncologyToday25/mBC/1/Presentation and evaluation ResearchToPractice.com/OncologyToday25/mBC/1/Presentation/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Hope S Rugo, MD
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California
Professor Emeritus, UCSF

Advisory Committees: Bristol Myers Squibb, Chugai Pharmaceutical Co Ltd, Napo Pharmaceuticals Inc, Sanofi, Viatris; Contracted Research (Institutional Research Support): Ambrx, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Stemline Therapeutics Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Gilead Sciences Inc.

Release date: July 2025
Expiration date: July 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Baird R et al. Puxitatug samrotecan (P-Sam, AZD8205) in patients with HR+/HER2– breast cancer: A first-in-human Phase 1/2a dose escalation and expansion study. ESMO Breast 2025;Abstract 300MO

Bardia A et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285-96. Abstract

Bardia A et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: Additional analysis from DESTINY-Breast06. San Antonio Breast Cancer Symposium 2024;Abstract LB1-04.

Bardia A et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 2024;391(22):2110-22. Abstract

Colombo R et al. The journey of antibody-drug conjugates: Lessons learned from 40 years of development. Cancer Discov 2024;14(11):2089-108. Abstract

Curigliano G et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). ASCO 2024;Abstract LBA1000.

Hamilton EP et al. Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study. ASCO 2025;Abstract LBA1000.

Khan A et al. Mechanisms and therapeutic strategies for endocrine resistance in breast cancer: A comprehensive review and meta-analysis. Cancers (Basel) 2025;17(10):1653. Abstract

Oliveira M et al. Primary results of SOLTI VALENTINE: Neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC). San Antonio Breast Cancer Symposium 2024;Abstract LBA1-06.

Pérez García JM et al. Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial. ASCO 2024;Abstract 1101.

Pistilli B et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial. ESMO Virtual Plenary 2023;Abstract VP1-2025